LSP (Life Sciences Partners), the leading life sciences investor in Europe, has recently announced that it has held its final close of LSP 6 at the $600 million (approx €530 million) hard cap. To date, this has been the largest fund ever raised in Europe focused on life sciences ventures.
With this funding, LSP currently has $1.1 billion (approx €965 million) of capital to invest across LSP 6, the LSP Health Economics Fund, and LSP’s public fund and mandates. Since 1988, LSP’s management has raised $2.5 billion (approx €2.2 billion) since it started to invest in the life sciences in 1988. The group has offices in Amsterdam, Munich, and Boston.
Attracted capital from diverse investor base!
Based out of Amsterdam, the company attracted capital from a diverse investor base, including pension funds, insurance companies, wealth managers, government funds and family offices. Most notably, the Dutch investment firm has commitments from Bristol Myers Squibb and Otsuka Pharmaceutical, validating LSP’s pivotal market position.
Companies developing new medical technologies!
For the uninitiated, LSP 6 will invest in 15-18, predominantly European private companies developing new medications or medical technologies, who turn cutting-edge scientific innovations into real-world healthcare solutions.
Built over 120 companies!
Founded by Clemens Van Blitterswijk and Rudy Dekeyser, LSP has built over 120 companies, many of which have brought breakthrough new medications or technologies to patients in large indications such as oncology, cardiology, or diabetes, but also in rare diseases.
René Kuijten, the Managing Partner of LSP, said:
We thank our loyal investors for their continued trust in LSP. Our track record, our long-standing in the industry, as well as our stable and experienced team of 30 professionals, have helped us raise this significant amount. The number of high-quality life sciences innovations in Europe is similar to the United States, but there is 5x less capital available to back these innovators and entrepreneurs. With our new fund, we can significantly contribute to the growth of our industry and ensure that European innovations get to patients faster.
Main image picture credits: Matej Kastelic/Shutterstock
Stay tuned to Silicon Canals for more European technology news.